Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Toth

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
American Journal of Therapeutics|June 1, 1994
Clinical Efficacy and Safety of Lower-Dose Indapamide Therapy in the Treatment of Patients with Mild to Moderate HypertensionRobert Weiss, Phillip Toth, E. Eugene Miller, et al.
Obesity (Silver Spring, Md.)|January 9, 2026
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE StudyHarold E Bays, Phillip Toth, Naim Alkhouri, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
American Journal of Therapeutics|June 1, 1994
Clinical Efficacy and Safety of Lower-Dose Indapamide Therapy in the Treatment of Patients with Mild to Moderate HypertensionRobert Weiss, Phillip Toth, E. Eugene Miller, et al.
Obesity (Silver Spring, Md.)|January 9, 2026
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE StudyHarold E Bays, Phillip Toth, Naim Alkhouri, et al.
Pageof 1